DDIT3 and heart failure: This revealed that those treated with R-CHOP plus bevacizumab had a three-fold increased risk of LVSD and heart failure compared with those treated with R-CHOP plus placebo with an incidence of 18 vs 8% and 16 vs 7%, respectively [178].